(VIANEWS) – RenaissanceRe Hold (RNR), MakeMyTrip Limited (MMYT), STAAR Surgical Company (STAA) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. RenaissanceRe Hold (RNR)
49.2% sales growth and 20.84% return on equity
RenaissanceRe Holdings Ltd., together with its subsidiaries, provides reinsurance and insurance products in the United States and internationally. The company operates through Property, and Casualty and Specialty segments. The Property segment writes property catastrophe excess of loss reinsurance and excess of loss reinsurance to insure insurance and reinsurance companies against natural and man-made catastrophes, including hurricanes, earthquakes, typhoons, and tsunamis, as well as winter storms, freezes, floods, fires, windstorms, tornadoes, explosions, and acts of terrorism; and other property class of products, such as proportional reinsurance, property per risk, property reinsurance, binding facilities, and regional U.S. multi-line reinsurance. The Casualty and Specialty segment writes various classes of products, such as directors and officers, medical malpractice, and professional indemnity; automobile and employer's liability, casualty clash, umbrella or excess casualty, workers' compensation, and general liability; financial and mortgage guaranty, political risk, surety, and trade credit; and accident and health, agriculture, aviation, cyber, energy, marine, satellite, and terrorism. The company distributes its products and services primarily through intermediaries. It also invests in and manages funds. RenaissanceRe Holdings Ltd. was founded in 1993 and is headquartered in Pembroke, Bermuda.
Earnings Per Share
As for profitability, RenaissanceRe Hold has a trailing twelve months EPS of $52.27.
PE Ratio
RenaissanceRe Hold has a trailing twelve months price to earnings ratio of 4.33. Meaning, the purchaser of the share is investing $4.33 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.84%.
Moving Average
RenaissanceRe Hold’s worth is way higher than its 50-day moving average of $204.61 and way above its 200-day moving average of $200.03.
2. MakeMyTrip Limited (MMYT)
22.5% sales growth and 5.58% return on equity
MakeMyTrip Limited, an online travel company, sells travel products and solutions in India, the United States, Singapore, Malaysia, Thailand, the United Arab Emirates, Peru, Colombia, and Indonesia. The company operates through three segments: Air Ticketing, Hotels and Packages, and Bus Ticketing. Its services and products include air tickets; hotels; packages; rail tickets; bus tickets; and car hire, as well as ancillary travel requirements, such as visa processing and facilitating access to travel insurance. The company allows travelers to research, plan, book, and purchase travel services and products through its Websites makemytrip.com, goibibo.com, redbus.in, makemytrip.com.sg, and makemytrip.ae; and other technology-enhanced distribution channels, such as call centers, travel stores, and travel agents' network, as well as mobile service platform. As of March 31, 2021, it had approximately 150 franchisee-owned travel stores. The company serves leisure and corporate travelers. MakeMyTrip Limited was incorporated in 2000 and is based in Gurugram, India.
Earnings Per Share
As for profitability, MakeMyTrip Limited has a trailing twelve months EPS of $0.46.
PE Ratio
MakeMyTrip Limited has a trailing twelve months price to earnings ratio of 120.41. Meaning, the purchaser of the share is investing $120.41 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.58%.
Moving Average
MakeMyTrip Limited’s value is way above its 50-day moving average of $45.93 and way above its 200-day moving average of $35.98.
Revenue Growth
Year-on-year quarterly revenue growth grew by 25.6%, now sitting on 728.16M for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 150% and 88.2%, respectively.
Yearly Top and Bottom Value
MakeMyTrip Limited’s stock is valued at $55.39 at 10:22 EST, below its 52-week high of $56.97 and way above its 52-week low of $22.50.
3. STAAR Surgical Company (STAA)
13.4% sales growth and 5.57% return on equity
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone intraocular lenses, as well as preloaded injectors for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. STAAR Surgical Company markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, and Italy. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Earnings Per Share
As for profitability, STAAR Surgical Company has a trailing twelve months EPS of $0.38.
PE Ratio
STAAR Surgical Company has a trailing twelve months price to earnings ratio of 73.34. Meaning, the purchaser of the share is investing $73.34 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.57%.
4. BioMarin Pharmaceutical (BMRN)
9.9% sales growth and 3.11% return on equity
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
Earnings Per Share
As for profitability, BioMarin Pharmaceutical has a trailing twelve months EPS of $0.77.
PE Ratio
BioMarin Pharmaceutical has a trailing twelve months price to earnings ratio of 118.01. Meaning, the purchaser of the share is investing $118.01 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.11%.
Sales Growth
BioMarin Pharmaceutical’s sales growth is 18.9% for the ongoing quarter and 9.9% for the next.
Yearly Top and Bottom Value
BioMarin Pharmaceutical’s stock is valued at $90.87 at 10:22 EST, way under its 52-week high of $117.49 and way higher than its 52-week low of $76.02.
Volume
Today’s last reported volume for BioMarin Pharmaceutical is 1104900 which is 38.61% below its average volume of 1800040.
Moving Average
BioMarin Pharmaceutical’s worth is under its 50-day moving average of $93.37 and above its 200-day moving average of $90.66.
5. Cinemark Holdings (CNK)
5.3% sales growth and 40.81% return on equity
Cinemark Holdings, Inc., together with its subsidiaries, engages in the motion picture exhibition business. As of October 8, 2021, it operated 521 theatres with 5,864 screens in the United States, and South and Central America. The company was founded in 1984 and is headquartered in Plano, Texas.
Earnings Per Share
As for profitability, Cinemark Holdings has a trailing twelve months EPS of $0.6.
PE Ratio
Cinemark Holdings has a trailing twelve months price to earnings ratio of 23.75. Meaning, the purchaser of the share is investing $23.75 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 40.81%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 84.1% and 66.7%, respectively.
Revenue Growth
Year-on-year quarterly revenue growth grew by 34.5%, now sitting on 3.03B for the twelve trailing months.
